CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter's five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Growing immunization programs & their increasing coverage
3.5.1.2.Increasing government support and investment
3.5.1.3.Development of novel vaccines
3.5.2.Restraints
3.5.2.1.High cost and unaffordability of safety syringes
3.5.2.2.Alternative modes of drug delivery
3.5.3.Opportunities
3.5.3.1.Rise in need for safety syringes in emerging economies
3.5.3.2.FDA approval to COVID 19 Vaccine
3.5.4.Impact analysis
3.6.Covid-19 Impact analysis on novel vaccine delivery system market

CHAPTER 4:NOVEL VACCINE DELIVERY SYSTEMS MARKET, BY DELIVERY MODE
4.1.Overview
4.1.1.Market size and forecast
4.2.Intradermal
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Subcutaneous
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Intramuscular
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country

CHAPTER 5:NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE
5.1.Overview
5.1.1.Market size and forecast
5.2.Syringe
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.2.4.Market size and forecast, by type
5.2.5.General Syringe
5.2.6.Smart Syringe
5.2.6.1.Market size and forecast
5.2.6.2.Smart Syringe, By type
5.2.6.3.smart syringe, market size and forecast, by type
5.2.6.3.1.Auto disable syringes, market size and forecast
5.2.6.3.2.Active safety syringes, market size and forecast
5.2.6.3.3.Passive safety syringes, market size and forecast
5.3.Needle-free Injection System
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast
5.3.3.Market analysis, by country
5.3.4.Market size and forecast, by type
5.3.5.Spring-based Injector Systems
5.3.5.1.Market size and forecast
5.3.6.Gas Propelled/Air Forced Injector Systems
5.3.6.1.Market size and forecast
5.3.7.Others
5.3.7.1.Market size and forecast
5.4.Others
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast
5.4.3.Market analysis, by country

CHAPTER 6:NOVEL VACCINE DELIVERY SYSTEM, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. Novel vaccine delivery system, by delivery mode
6.2.2.1.2.U.S. Novel vaccine delivery system, by device
6.2.2.2.Canada
6.2.2.2.1.Canada Novel vaccine delivery system, by delivery mode
6.2.2.2.2.Canada Novel vaccine delivery system, by device
6.2.2.3.Mexico
6.2.2.3.1.Mexico Novel vaccine delivery system, by delivery mode
6.2.2.3.2.Mexico Novel vaccine delivery system, by device
6.2.3.North America market size and forecast, by delivery mode
6.2.4.North America market size and forecast, by device
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany Novel vaccine delivery system, by delivery mode
6.3.2.1.2.Germany Novel vaccine delivery system, by device
6.3.2.2.France
6.3.2.2.1.France Novel vaccine delivery system, by delivery mode
6.3.2.2.2.France Novel vaccine delivery system, by device
6.3.2.3.UK
6.3.2.3.1.UK Novel vaccine delivery system, by delivery mode
6.3.2.3.2.UK Novel vaccine delivery system, by device
6.3.2.4.Italy
6.3.2.4.1.Italy Novel vaccine delivery system, by delivery mode
6.3.2.4.2.Italy Novel vaccine delivery system, by device
6.3.2.5.Spain
6.3.2.5.1.Spain Novel vaccine delivery system, by delivery mode
6.3.2.5.2.Spain Novel vaccine delivery system, by device
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe Novel vaccine delivery system, by delivery mode
6.3.2.6.2.Rest of Europe Novel vaccine delivery system, by device
6.3.3.Europe market size and forecast, by delivery mode
6.3.4.Europe market size and forecast, by device
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan
6.4.2.1.1.Japan Novel vaccine delivery system, by delivery mode
6.4.2.1.2.Japan Novel vaccine delivery system, by device
6.4.2.2.China
6.4.2.2.1.China Novel vaccine delivery system, by delivery mode
6.4.2.2.2.China Novel vaccine delivery system, by device
6.4.2.3.Australia
6.4.2.3.1.Australia Novel vaccine delivery system, by delivery mode
6.4.2.3.2.Australia Novel vaccine delivery system, by device
6.4.2.4.India
6.4.2.4.1.India Novel vaccine delivery system, by delivery mode
6.4.2.4.2.India Novel vaccine delivery system, by device
6.4.2.5.South Korea
6.4.2.5.1.South Korea Novel vaccine delivery system, by delivery mode
6.4.2.5.2.South Korea Novel vaccine delivery system, by device
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific Novel vaccine delivery system, by delivery mode
6.4.2.6.2.Rest of Asia-Pacific Novel vaccine delivery system, by device
6.4.3.Asia-Pacific market size and forecast, by delivery mode
6.4.4.Asia-Pacific market size and forecast, by device
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil Novel vaccine delivery system, by delivery mode
6.5.2.1.2.Brazil Novel vaccine delivery system, by device
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia Novel vaccine delivery system, by delivery mode
6.5.2.2.2.Saudi Arabia Novel vaccine delivery system, by device
6.5.2.3.South Africa
6.5.2.3.1.South Africa Novel vaccine delivery system, by delivery mode
6.5.2.3.2.South Africa Novel vaccine delivery system, by device
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA Novel vaccine delivery system, by delivery mode
6.5.2.4.2.Rest of LAMEA Novel vaccine delivery system, by device
6.5.3.LAMEA market size and forecast, by delivery mode
6.5.4.LAMEA market size and forecast, by device

CHAPTER 7:COMPANY PROFILES
7.1.CAPITAL PARTNERS, LLC (KINDEVA DRUG DELIVERY)
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BECTON, DICKINSON, AND COMPANY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance.
7.3.CARL ZEISS FOUNDATION (SCHOTT AG)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.GERRESHEIMER AG
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.GURNET POINT CAPITAL (CORIUM INTERNATIONAL INC.)
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance.
7.6.INOVIO PHARMACEUTICALS, INC. (BIOJECT MEDICAL TECHNOLOGIES)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.PHARMAJET, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.RETRACTABLE TECHNOLOGIES, INC.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.TERUMO CORPORATION
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.VAXXAS PTY LTD
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
7.10.6.Key strategic moves and developments

List of Tables

TABLE 01.GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET, BY DELIVERY MODE, 2020-2030($MILLION)
TABLE 02.INTRAMUSCULAR NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 03.INTRADERMAL NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 04.SUBCUTANEOUS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 05.OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 06.GLOBAL NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030($MILLION)
TABLE 07.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY REGION, 2020-2030($MILLION)
TABLE 08.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY TYPE, 2020-2030, ($MILLION)
TABLE 09.NEEDLE FREE INJECTION SYSTEM NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 10.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR NEEDLE FREE INJECTION SYSTEM, BY TYPE, 2020-2030, ($MILLION)
TABLE 11.OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 12.NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 13.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 14.U.S. NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 15.U.S. NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 16.CANADA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 17.CANADA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 18.MEXICO NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 19.MEXICO NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 20.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 21.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 22.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 23.GERMANY NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 24.GERMANY NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 25.FRANCE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 26.FRANCE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 27.UK NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 28.UK NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 29.ITALY NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 30.ITALY NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 31.SPAIN NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 32.SPAIN NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 33.REST OF EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 34.REST OF EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 35.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 36.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 37.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 38.JAPAN NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 39.JAPAN NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 40.CHINA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 41.CHINA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 42.AUSTRALIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 43.AUSTRALIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 44.INDIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 45.INDIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 46.SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 47.SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 48.REST OF ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 49.REST OF ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 50.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 51.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 52.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 53.BRAZIL NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 54.BRAZIL NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 55.SAUDI ARABIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 56.SAUDI ARABIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 57.SOUTH AFRICA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 58.SOUTH AFRICA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 59.REST OF LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 60.REST OF LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 61.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 62.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 63.ALTARIS: COMPANY SNAPSHOT
TABLE 64.ALTARIS: PRODUCT PORTFOLIO
TABLE 65.BD: COMPANY SNAPSHOT
TABLE 66.BD: OPERATING SEGMENTS
TABLE 67.BD: PRODUCT PORTFOLIO
TABLE 68.BD: NET SALES, 2018-2020 ($MILLION)
TABLE 69.BD: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 70.BD: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 71.CARL ZEISS: COMPANY SNAPSHOT
TABLE 72.CARL ZEISS: PRODUCT PORTFOLIO
TABLE 73.GERRESHEIMER: COMPANY SNAPSHOT
TABLE 74.GERRESHEIMER: OPERATING SEGMENTS
TABLE 75.GERRESHEIMER: PRODUCT PORTFOLIO
TABLE 76.GERRESHEIMER: NET SALES, 2018-2020 ($MILLION)
TABLE 77.GERRESHEIMER: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 78.GERRESHEIMER: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 79.GURNET POINT: COMPANY SNAPSHOT
TABLE 80.GURNET POINT: PRODUCT PORTFOLIO
TABLE 81.INOVIO: COMPANY SNAPSHOT
TABLE 82.INOVIO: PRODUCT PORTFOLIO
TABLE 83.INOVIO: NET SALES, 2018-2020 ($MILLION)
TABLE 84.PHARMAJET: COMPANY SNAPSHOT
TABLE 85.PHARMAJET: OPERATING SEGMENT
TABLE 86.PHARMAJET: PRODUCT PORTFOLIO
TABLE 87.RETRACTABLE TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 88.RETRACTABLE: PRODUCT PORTFOLIO
TABLE 89.RETRACTABLE TECHNOLOGIES: NET SALES, 2018-2020 ($MILLION)
TABLE 90.RETRACTABLE TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 91.RETRACTABLE TECHNOLOGIES: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 92.TERUMO: COMPANY SNAPSHOT
TABLE 93.TERUMO: OPERATING SEGMENTS
TABLE 94.TERUMO: PRODUCT PORTFOLIO
TABLE 95.TERUMO: NET SALES, 2018-2020 ($MILLION)
TABLE 96.TERUMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 97.TERUMO: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 98.VAXXAS: COMPANY SNAPSHOT
TABLE 99.VAXXAS: PRODUCT PORTFOLIO

List of Figures

FIGURE 01.GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.HIGH INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF INTRAMUSCULAR NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF INTRADERMAL NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF SUBCUTANEOUS NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF OTHER NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13.CONVENTIONAL SYRINGE MARKET, 2020-2030, ($MILLION)
FIGURE 14.SMART SYRINGE MARKET, 2020-2030, ($MILLION)
FIGURE 15.GLOBAL SMART SYRINGE MARKET, BY TYPE, 2020-2030 ($MILLION)
FIGURE 16.GLOBAL SMART SYRINGE MARKET FOR ACTIVE SAFETY SYRINGES, BY TYPE 2020-2030 ($MILLION)
FIGURE 17.GLOBAL SMART SYRINGE MARKET FOR PASSIVE SAFETY SYRINGES, BY TYPE, 2020-2030 ($MILLION)
FIGURE 18.GLOBAL SMART SYRINGE MARKET FOR AUTO DISABLE SYRINGES, BY TYPE 2020-2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF NEEDLE FREE INJECTION SYSTEM NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.SPRING-BASED INJECTOR SYSTEMS MARKET, 2020-2030, ($MILLION)
FIGURE 21.GAS PROPELLED/AIR FORCED INJECTOR SYSTEMS MARKET, 2020-2030, ($MILLION)
FIGURE 22.OTHERS MARKET, 2020-2030, ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)

Companies Mentioned
Altaris Capital Partners, LLC (Kindeva Drug Delivery), Becton, Dickinson, and Company, Carl Zeiss Foundation (Schott AG), Gerresheimer AG, Gurnet Point Capital (Corium International Inc.), Inovio Pharmaceuticals, Inc. (Bioject Medical Technologies), PharmaJet, Inc., Retractable Technologies, Inc., Terumo Corporation, and VAXXAS Pty Ltd.